N. Yu. Mironov - Concepedia

Author

N. Yu. Mironov

National Medical Research Center of Cardiology ORCID

Also Known As

N Iu Mironov, N Y Mironov, N. Mironov, N. U. Mironov, N. Y. Mironov, N. Yu Mironov, N. Yu. Mironov, N.Y. Mironov, N.Yu. Mironov, N.Yu. Mironov Mironov

Publications

522

Citations

H-Index

Concepts

All Affiliations

National Medical Research Center of Cardiology Institute of Experimental Cardiology

About

N. Yu. Mironov is an author at National Medical Research Center of Cardiology specializing in public health, anesthesiology, and cardiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	373
2	Public Health	6	6	373
3	Emergency Medicine	3	3	300
4	Cardiothoracic Surgery	1	1	212
5	Pharmacology	1	1	24

N. Yu. Mironov

Publications

436

Citations

H-Index

Page 1

	Year	Citations
2020 Clinical guidelines for Atrial fibrillation and atrial flutter M. S. Arakelyan, L.A. Bockeriа, Elena Vasilieva, Russian Journal of Cardiology Electrophysiological EvaluationCardiothoracic SurgeryStructural Heart DiseaseCardiovascular DiseaseRussian Society	2021	212
Ventricular arrhythmias. Ventricular tachycardias and sudden cardiac death. 2020 Clinical guidelines N. M. Neminuschiy, V. V. Bereznitskaya, S. V. Garkina, Russian Journal of Cardiology Ventricular ArrhythmiasClinical GuidelinesRussian SocietyRussian Scientific SocietyElectrophysiological Evaluation	2021	72
Safety and Effectiveness of Electrical and Pharmacological Cardioversion in Persistent Atrial Fibrillation. Part I: Study Rationale, Design and Assessment of Effectiveness N. Yu. Mironov, V. V. Vlodzyanovskiy, Golitsyn Sp, Rational Pharmacotherapy in Cardiology Cardiac AnaesthesiaDevice TherapyCardiovascular PharmacologyPharmacotherapyThrombosis	2018	29
Safety and Effectiveness of Pharmacologic Conversion of Atrial Fibrillation and Flutter: Results of Multicenter Trial. Part I: Study Rationale, Design and Assessment of Effectiveness N. Yu. Mironov, V. V. Vlodzyanovskiy, Golitsyn Sp, Rational Pharmacotherapy in Cardiology Cardiac AnaesthesiaTotal DoseCardiovascular PharmacologyPharmacotherapyCardiovascular Toxicity	2021	24
EURASIAN CLINICAL RECOMMENDATIONS ON DIAGNOSIS AND TREATMENT OF ATRIAL FIBRILLATION Golitsyn Sp, L. Yu. Layovich, N. Yu. Mironov Eurasian heart journal ThrombosisElectrophysiological EvaluationCardiovascular DiseaseCoagulopathyAtrial Fibrillation	2019	20
Refralon (niferidil) is a new class III antiarrhythmic agent for pharmacological cardioversion for persistent atrial fibrillation and atrial flutter E. B. Maykov, N. Yu. Mironov, Golitsyn Sp, Terapevticheskii arkhiv	2015	18
Safety and Effectiveness of Electrical and Pharmacological Cardioversion in Persistent Atrial Fibrillation. Part 2: Assessment of Safety N. Yu. Mironov, V. V. Vlodzyanovskiy, Golitsyn Sp, Rational Pharmacotherapy in Cardiology Cardiac AnaesthesiaCardiovascular PharmacologyPharmacotherapyThrombosisElectrophysiological Evaluation	2019	16
Atrial fibrillation and chronic heart failure: interrelationship and approaches to treatment D. A. Gagloeva, N. Yu. Mironov, L.Yu. Lajovich, Russian Cardiology Bulletin	2021	15
Efficacy of a New Class III Drug Niferidil in Cardioversion of Persistent Atrial Fibrillation and Flutter E. B. Maykov, Yulia A. Yuricheva, N. Yu. Mironov, Journal of Cardiovascular Pharmacology	2014	10
Recent advances in diagnosis and management of atrial fibrillation N. Yu. Mironov, Lada Yu. Laiovich, T. V. Sharf, Terapevticheskii arkhiv	2019	10

Page 1